Clinically validated
Saturday, March 12th, 2022
|
Tested in clinical setting |
Follow-up |
Diagnostics / Hematuria |
|---|---|---|
| Highly Sensitive | (100%) | (100%) |
| Highly Specific | (97.3%) | (83,3%) |
|
Tested in clinical setting |
Follow-up |
Diagnostics / Hematuria |
|---|---|---|
| Highly Sensitive | (100%) | (100%) |
| Highly Specific | (97.3%) | (83,3%) |
The test is currently performed as a service at Uromonitor, hosted at the above mentioned institutions.
To access the service, urologists in hospitals and clinics should first have materials for urine collection and shipment.
Direct ordering the complete analysis kit to be performed in a laboratory or medical unit.
Recommended for professionals!
“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.
Uromonitor is easy and can deliver reliable results to reduce costs with follow-up”.
